Abcellera Biologics Company Leadership
| ABCL Stock | USD 3.01 0.01 0.33% |
Abcellera Biologics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Abcellera Biologics suggests that most insiders are extremely bullish. Abcellera Biologics employs about 586 people. The company is managed by 19 executives with a total tenure of roughly 1368 years, averaging almost 72.0 years of service per executive, having 30.84 employees per reported executive.
Abcellera Biologics' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2023-05-26 | Holdings Ltd. Thermopylae | Acquired 153000 @ 6.52 | View | ||
| 2022-12-16 | Holdings Ltd. Thermopylae | Acquired 85102 @ 10.1 | View | ||
| 2022-08-19 | Holdings Ltd. Thermopylae | Acquired 200000 @ 11.46 | View | ||
| 2022-06-13 | Holdings Ltd. Thermopylae | Acquired 54915 @ 8.03 | View | ||
| 2022-06-06 | Holdings Ltd. Thermopylae | Acquired 64545 @ 7.5 | View | ||
| 2022-05-16 | Veronique Lecault | Acquired 200000 @ 6.34 | View | ||
| 2022-05-12 | Holdings Ltd. Thermopylae | Acquired 1408468 @ 6.41 | View | ||
| 2022-03-04 | John S Montalbano | Acquired 10000 @ 8.54 | View | ||
| 2022-03-01 | John S Montalbano | Acquired 20000 @ 9.05 | View | ||
| 2022-02-28 | Veronique Lecault | Acquired 230789 @ 8.66 | View | ||
| 2021-12-03 | Andrew Lo | Acquired 86938 @ 14.02 | View |
Monitoring Abcellera Biologics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Abcellera |
Abcellera Biologics Management Team Effectiveness
The company has return on total asset (ROA) of (0.1326) % which means that it has lost $0.1326 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1555) %, meaning that it created substantial loss on money invested by shareholders. Abcellera Biologics' management efficiency ratios could be used to measure how well Abcellera Biologics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to -0.11 this year. Return On Capital Employed is expected to rise to -0.16 this year. At this time, Abcellera Biologics' Net Tangible Assets are quite stable compared to the past year. Non Currrent Assets Other is expected to rise to about 99 M this year, although the value of Non Current Assets Total will most likely fall to about 317.1 M.Common Stock Shares Outstanding is expected to rise to about 290.3 M this year, although the value of Net Income Applicable To Common Shares will most likely fall to about 94.4 M.
Abcellera Biologics Workforce Comparison
Abcellera Biologics is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 826. Abcellera Biologics totals roughly 586 in number of employees claiming about 71% of equities under Health Care industry.
Abcellera Biologics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Abcellera Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Abcellera Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Abcellera Biologics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-12-01 | 1.0 | 1 | 1 | 56,125 | 56,125 |
| 2024-09-01 | 2.0 | 2 | 1 | 339,641 | 56,125 |
| 2024-06-01 | 2.5 | 5 | 2 | 631,261 | 139,459 |
| 2024-03-01 | 5.0 | 5 | 1 | 4,308,822 | 56,125 |
| 2023-12-01 | 1.5 | 3 | 2 | 86,125 | 266,125 |
| 2023-09-01 | 4.0 | 4 | 1 | 126,125 | 56,125 |
| 2023-06-01 | 2.0 | 4 | 2 | 473,625 | 306,125 |
| 2023-03-01 | 1.0 | 1 | 1 | 56,125 | 56,125 |
| 2022-12-01 | 2.5 | 10 | 4 | 2,553,086 | 226,125 |
| 2022-09-01 | 2.0 | 2 | 1 | 256,125 | 56,125 |
| 2022-06-01 | 8.0 | 8 | 1 | 2,178,226 | 56,125 |
| 2022-03-01 | 4.0 | 4 | 1 | 316,914 | 56,125 |
| 2021-12-01 | 4.0 | 16 | 4 | 3,683,985 | 974,500 |
| 2021-09-01 | 2.0 | 6 | 3 | 1,489,564 | 1,175,000 |
| 2021-06-01 | 0.4667 | 7 | 15 | 2,681,117 | 28,431,753 |
| 2021-03-01 | 1.0 | 1 | 1 | 1,000,000 | 1,000,000 |
| 2020-12-01 | 2.6364 | 29 | 11 | 76,021,591 | 6,188,194 |
Abcellera Biologics Notable Stakeholders
An Abcellera Biologics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Abcellera Biologics often face trade-offs trying to please all of them. Abcellera Biologics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Abcellera Biologics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Carl Hansen | President CEO | Profile | |
| Graham MSc | Director Development | Profile | |
| Veronique Lecault | COO Director | Profile | |
| Bo Barnhart | Scientific Director | Profile | |
| Andrew MBA | Chief Officer | Profile | |
| Paul Colussi | Site Technologies | Profile | |
| JD Esq | Chief Officer | Profile | |
| Murray McCutcheon | Senior Partnering | Profile | |
| M CIPD | Sr Culture | Profile | |
| Ester Falconer | Chief Officer | Profile | |
| Alexandra MSc | Ma Communications | Profile | |
| Esq JD | CCO, Officer | Profile | |
| Janna Bednenko | Head Genetics | Profile | |
| Josephine Hellschlienger | Manager Relations | Profile | |
| Adam MAICD | Senior Discovery | Profile | |
| Tiffany BSc | VP Communications | Profile | |
| Neil MBA | Chief Officer | Profile | |
| CGA CPA | Senior Accounting | Profile | |
| Kathleen BA | Head Communications | Profile |
About Abcellera Biologics Management Performance
The success or failure of an entity such as Abcellera Biologics often depends on how effective the management is. Abcellera Biologics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Abcellera management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Abcellera management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.11) | (0.11) | |
| Return On Capital Employed | (0.17) | (0.16) | |
| Return On Assets | (0.10) | (0.09) | |
| Return On Equity | (0.13) | (0.12) |
Abcellera Biologics Workforce Analysis
Traditionally, organizations such as Abcellera Biologics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Abcellera Biologics within its industry.Abcellera Biologics Manpower Efficiency
Return on Abcellera Biologics Manpower
| Revenue Per Employee | 64.9K | |
| Revenue Per Executive | 2M | |
| Net Loss Per Employee | 249.8K | |
| Net Loss Per Executive | 7.7M | |
| Working Capital Per Employee | 1.3M | |
| Working Capital Per Executive | 39.6M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.459 | Earnings Share (0.61) | Revenue Per Share 0.112 | Quarterly Revenue Growth (0.01) | Return On Assets (0.13) |
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.